Distal humeral fractures are a common injury that can have a significant impact on a patient’s quality of life. Treatment of these fractures is challenging due to the complex anatomy of the elbow, the need for precise alignment of the fracture fragments, and the need to achieve a stable construct. The traditional approach to treating distal humeral fractures has been to use open reduction and internal fixation (ORIF). However, recent advances in technology have enabled a new approach to treating distal humeral fractures that is less invasive, more accurate, and more stable. This new approach is revolutionizing the treatment of distal humeral fractures and providing better outcomes for patients.
The elbow is a complex joint that is made up of three bones: the humerus, the ulna, and the radius. The humerus is the long bone of the upper arm that connects the shoulder to the elbow. The ulna and radius are the two bones of the forearm. The distal humerus is the lower end of the humerus and is made up of three separate parts: the capitellum, the trochlea, and the olecranon. The capitellum is the rounded end of the humerus that articulates with the radius. The trochlea is the curved part of the humerus that articulates with the ulna. The olecranon is the bony prominence at the back of the elbow and is the point of attachment for the triceps muscle.
Distal humeral fractures occur when there is a break in the bones of the distal humerus. These fractures can range from simple, isolated fractures of the capitellum or trochlea to complex fractures involving multiple parts of the distal humerus. The most common cause of distal humeral fractures is trauma, such as a fall or direct blow to the elbow. Distal humeral fractures can also occur as a result of osteoporosis or other bone-weakening diseases.
The traditional approach to treating distal humeral fractures has been open reduction and internal fixation (ORIF). This involves making an incision in the skin to expose the fracture, reducing the fracture fragments to their anatomic position, and then securing them in place with plates and screws. This approach has been successful in treating many distal humeral fractures, but it can be challenging due to the complex anatomy of the elbow and the need for precise alignment of the fracture fragments.
Recent advances in technology have enabled a new approach to treating distal humeral fractures that is less invasive, more accurate, and more stable. This approach is known as percutaneous reduction and internal fixation (PRIF). PRIF involves using image guidance to precisely align the fracture fragments and then securing them in place with specially designed implants. The advantages of PRIF over ORIF include less tissue trauma, less blood loss, less risk of infection, shorter operating times, and improved accuracy of fracture reduction.
The new approach to treating distal humeral fractures is revolutionizing the way these fractures are treated. PRIF is less invasive, more accurate, and more stable than ORIF, and it is providing better outcomes for patients. The future of distal humeral fracture treatment is likely to involve the continued development of new, more advanced techniques to improve the accuracy and stability of fracture fixation.
Distal humeral fractures are a common injury that can have a significant impact on a patient’s quality of life. Treatment of these fractures is challenging due to the complex anatomy of the elbow, the need for precise alignment of the fracture fragments, and the need to achieve a stable construct. The traditional approach to treating distal humeral fractures has been open reduction and internal fixation (ORIF), but recent advances in technology have enabled a new approach to treating distal humeral fractures that is less invasive, more accurate, and more stable. This new approach is revolutionizing the treatment of distal humeral fractures and providing better outcomes for patients.
1.
Charles III, King of Kings, is Cancerous.
2.
Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.
3.
Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival
4.
Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.
5.
WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research
1.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
2.
Ultimate Guide to Oncology Services in the USA
3.
Unveiling New Hope: Potential Therapeutic Targets in Hematological Malignancies
4.
Real-World Oncology Insights: CAR-T, Immunotherapy, PROs, and Digital Tools
5.
Introducing the Corrected Calcium Calculator: A Revolutionary Tool in Medical Assessment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Oropharyngeal Cancer in Relation to HPV Status
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
3.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation